Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: Mark Fowler who wrote (140608)	3/15/2002 12:34:36 PM
From: H James Morris	Respond to of 164684

ImClone executive's daughter sold stock The daughter of Samuel Waksal, the chief executive of ImClone Systems Inc., sold $2.46 million of company stock the day before federal regulators rejected ImClone's drug application. Aliza Waksal is not considered a corporate insider and the transaction could very well be legal. Still, it adds to the company's deteriorating credibility with investors, many of whom have sued the company in recent months alleging stock fraud. According to a filing with the Securities and Exchange Commission, Aliza Waksal sold the stock on Dec. 27. On Dec. 28, the Food and Drug Administration refused to considered ImClone's application to market the highly touted cancer fighting drug, Erbitux.